Roche’s investigational obesity drug CT-388 delivers dramatic weight loss in Phase II trial
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The newly certified kits are designed for early detection and large-scale screening programs
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
Subscribe To Our Newsletter & Stay Updated